Decision Diagnostics Corp. (DECN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Decision Diagnostics Corp. (DECN) trades at $0.00 with AI Score 48/100 (Grade C). Decision Diagnostics Corp. (DECN) is a healthcare company focused on developing smartphone-based electronic medical record technologies and home-use diagnostic solutions. Market cap: $35,450, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for DECN: DECN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DECN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DECN: the 1 perspectives are evenly split.
How is this calculated? →Decision Diagnostics Corp. (DECN) Healthcare & Pipeline Overview
Decision Diagnostics Corp. (DECN) specializes in smartphone-based electronic medical record technologies and glucose monitoring solutions, catering to both human and veterinary markets, with a focus on innovative home-use diagnostic products.
What Is the Investment Thesis for DECN?
Decision Diagnostics Corp. (DECN) operates in a niche market characterized by a growing demand for mobile health solutions and home diagnostics. The company's focus on glucose monitoring products positions it well within the expanding diabetes care market, projected to reach $32 billion by 2027. DECN's proprietary products, such as the GenUltimate! glucose test strips and the GenUltimate! 4Pets system, provide unique offerings that cater to both human and veterinary health, potentially driving revenue growth. The company's ongoing efforts to acquire and maintain intellectual property could further enhance its competitive edge. However, the significant negative profit margin of -1499.1% indicates that the company is currently facing financial challenges, which could impact its ability to invest in growth initiatives. As the healthcare sector increasingly shifts towards mobile solutions, DECN's innovations may capture market share, but the company must navigate regulatory hurdles and market competition effectively.
Based on FMP financials and quantitative analysis
DECN Key Highlights
- Market Cap: $0.00B, indicating a current valuation challenge.
- Profit Margin: -1499.1%, reflecting ongoing financial difficulties.
- Gross Margin: 25.2%, indicating some profitability in product sales.
- Beta: -0.05, suggesting low volatility compared to the market.
- No dividend yield, indicating a focus on reinvestment rather than shareholder returns.
Who Are DECN's Competitors?
DECN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $318.27 | -0.40% | $6.38B | 99 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| SDGCF Sundrug Co.,Ltd. | $30.97 | +9.90% | $3.62B | 48 |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | 48 |
| MYCOF Noveris Health Sciences Inc. | $2.00 | +0.00% | $117.10M | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DECN's Key Strengths?
- Innovative product offerings in glucose monitoring.
- Strong intellectual property portfolio.
- Expertise in mobile health technologies.
- Diverse revenue streams from both human and veterinary markets.
What Are DECN's Weaknesses?
- Significant negative profit margin indicating financial challenges.
- Small team size may limit operational capacity.
- Limited brand recognition compared to larger competitors.
- Dependence on a niche market may restrict growth potential.
What Could Drive DECN Stock Higher?
- Expansion of the product line with new glucose monitoring technologies.
- Development of software solutions for enhanced patient care management.
- Active engagement in acquiring new patents and intellectual property.
- Potential partnerships with healthcare providers to enhance product distribution.
- Focus on increasing brand recognition in the veterinary diagnostics market.
What Are the Key Risks for DECN?
- Financial-distress signal — its Altman Z-Score of -22.72 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles could delay product launches and market entry.
- Financial instability indicated by a negative profit margin may limit growth.
- Increased competition from larger pharmaceutical companies may impact market share.
- Dependence on a niche market may restrict revenue growth opportunities.
What Are the Growth Opportunities for DECN?
- Growth opportunity 1: The global diabetes care market is projected to reach $32 billion by 2027, driven by an increasing prevalence of diabetes and a growing demand for home monitoring solutions. Decision Diagnostics Corp.'s focus on glucose monitoring products positions it well to capture a share of this expanding market, particularly through its innovative GenUltimate! glucose test strips.
- Growth opportunity 2: The veterinary diagnostics market is also on the rise, with an increasing number of pet owners seeking at-home health monitoring solutions for their animals. DECN's PetSure! glucose test strips and the GenUltimate! 4Pets system cater to this demand, providing a unique competitive advantage in a niche market that is expected to grow significantly in the coming years.
- Growth opportunity 3: The increasing adoption of telemedicine and mobile health solutions presents a substantial opportunity for Decision Diagnostics. By enhancing its mobile-centric e-health products and integrating them with existing healthcare systems, the company could tap into the growing trend of remote patient monitoring, thereby expanding its customer base and revenue streams.
- Growth opportunity 4: The company's portfolio of intellectual property, including patents and trademarks, offers potential for licensing agreements and collaborations with larger healthcare organizations. This could provide additional revenue streams and enhance DECN's market presence without the need for significant capital investment.
- Growth opportunity 5: The ongoing development of software solutions like MD@Hand and Practice Probe positions DECN to capitalize on the trend towards integrated healthcare management systems. As healthcare providers increasingly seek comprehensive solutions to manage patient care, DECN's offerings could become essential tools, driving both sales and partnerships.
What Opportunities Does DECN Have?
- Growing global diabetes care market presents expansion potential.
- Increasing demand for veterinary health monitoring solutions.
- Rising adoption of telemedicine and mobile health technologies.
- Potential for licensing agreements to enhance revenue.
What Threats Does DECN Face?
- Intense competition from larger healthcare companies.
- Regulatory hurdles in the healthcare industry.
- Market volatility affecting funding and investment.
- Rapid technological advancements requiring continuous innovation.
What Are DECN's Competitive Advantages?
- Unique product offerings in glucose monitoring for both humans and pets.
- Strong portfolio of intellectual property, including patents and trademarks.
- Focus on mobile-centric solutions that align with current healthcare trends.
- Established relationships with healthcare providers and organizations.
- Innovative software solutions that enhance patient care management.
What Does DECN Do?
Founded in 2000 and headquartered in Westlake Village, California, Decision Diagnostics Corp. (DECN) has established itself as a key player in the healthcare sector, particularly in the development of electronic medical record (EMR) technologies optimized for smartphones. Originally known as InstaCare Corp., the company rebranded to Decision Diagnostics in November 2011 to better reflect its focus on diagnostics and healthcare solutions. DECN's product offerings are diverse, including regulated and unregulated diagnostic solutions, home-use testing products for chronic illness management, and direct-to-patient logistics for diabetes programs. A significant portion of their product line revolves around glucose monitoring, featuring the GenUltimate! glucose test strips, which are classified as Class II medical devices for personal at-home use. Additionally, the company caters to the veterinary market with PetSure! glucose test strips designed for dogs and cats, and the proprietary GenUltimate! 4Pets Glucose system for testing glucose levels in various animals. Beyond product development, Decision Diagnostics actively manages a portfolio of intellectual property, including patents and trademarks. Their software solutions, such as MD@Hand, Practice Probe, and ResidenceWare, enhance patient care management and streamline communication in residential management. With a small team of six employees, DECN continues to innovate in the healthcare technology landscape, aiming to provide essential tools for healthcare professionals at the point of care.
What Products and Services Does DECN Offer?
- Develop smartphone-based electronic medical record technologies.
- Manufacture glucose monitoring products for humans and pets.
- Provide home-use testing solutions for chronic illness management.
- Facilitate direct-to-patient logistics for diabetes programs.
- Offer software solutions for healthcare management and data mining.
- Acquire and maintain a portfolio of intellectual property related to healthcare technologies.
How Does DECN Make Money?
- Generate revenue through the sale of glucose monitoring products and test strips.
- Offer software solutions that enhance patient care management for healthcare providers.
- Engage in licensing agreements for proprietary technology and intellectual property.
- Provide fulfillment services for diabetes management programs.
- Capitalize on both regulated and unregulated diagnostic solutions.
What Industry Does DECN Operate In?
The healthcare industry, particularly the medical pharmaceuticals sector, is experiencing significant growth driven by technological advancements and an increasing focus on personalized medicine. The global diabetes care market is expected to expand rapidly, with a projected CAGR of 8.6% from 2020 to 2027. Decision Diagnostics Corp. operates within this dynamic landscape, focusing on mobile health and home diagnostics, which are becoming increasingly important as patients seek convenient and accessible healthcare solutions. The competitive landscape includes major players like Ligand Pharmaceuticals (LGND), which emphasizes the need for DECN to differentiate its offerings and maintain a strong market presence.
Who Are DECN's Key Customers?
- Healthcare providers seeking innovative diagnostic solutions.
- Individuals managing chronic illnesses, particularly diabetes.
- Veterinary clinics and pet owners requiring glucose monitoring for animals.
- Healthcare organizations interested in integrated software solutions.
- Research institutions looking for diagnostic technologies.
Company Profile
Decision Diagnostics Corp. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO Keith Berman. DECN has traded publicly since 2002.
How Decision Diagnostics Corp. Is Valued
Decision Diagnostics Corp. carries a market capitalization of 35K, placing it in the micro-cap category. Relative to its peer group, DECN's quantitative score of 48/100 is below the peer average of 70/100.
F-Score 3/9Financial Health
Decision Diagnostics Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.72 places it in the distress zone, a signal of elevated financial risk.
DECN Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's direction, indicating potential growth.
- Community sentiment has shifted positively as discussions around product innovations have gained traction.
- Increased media attention on the company's advancements in diagnostics technology has boosted its visibility.
- Recent partnerships or collaborations may enhance market reach and product offerings, aligning with industry trends.
Bear Case
- Concerns over the company's financial stability have surfaced, leading to skepticism among investors.
- Social sentiment has shown a level of frustration regarding slow product rollout timelines, impacting trust.
- Negative community discussions highlight potential regulatory hurdles that could delay progress.
- Market perception remains cautious due to historical volatility and uncertainty in the diagnostics sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DECN Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
DECN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DECN.
Price Targets
Wall Street price target analysis for DECN.
DECN MoonshotScore
What does this score mean?
The MoonshotScore rates DECN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Keith Berman
CEO
Keith Berman has been at the helm of Decision Diagnostics Corp. since its inception in 2000. With a background in healthcare technology and management, he has played a pivotal role in shaping the company's strategic direction. Under his leadership, DECN has focused on developing innovative diagnostic solutions that cater to both human and veterinary markets.
Track Record: Keith Berman has successfully guided Decision Diagnostics through various phases of product development and market entry, establishing a strong portfolio of glucose monitoring products. His leadership has been instrumental in the company's rebranding and focus on mobile health technologies.
DECN OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often resulting in lower visibility and trading volumes. Companies in this tier may have less stringent reporting requirements, which can affect transparency and investor confidence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure may lead to uncertainty regarding the company's performance.
- Lower trading volumes can result in increased volatility and price fluctuations.
- Potential regulatory scrutiny may affect operations and market access.
- Competition from larger, more established companies may hinder growth.
- Verify the company's financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Examine the regulatory environment affecting the company's products.
- Review the management team's experience and track record.
- Investigate potential partnerships or collaborations.
- Established since 2000, indicating a long history in the industry.
- Diverse product offerings in both human and veterinary markets.
- Active portfolio of intellectual property, including patents.
DECN Healthcare Stock FAQ
What does Decision Diagnostics Corp. do?
Decision Diagnostics Corp. specializes in developing smartphone-based electronic medical record technologies and home-use diagnostic solutions. The company offers a range of products, including glucose monitoring systems for humans and pets, as well as software solutions that enhance patient care management. Their focus on mobile health technologies positions them uniquely in the healthcare market, catering to both individual patients and healthcare providers.
What are the main risks for DECN?
Decision Diagnostics Corp. faces several risks, including regulatory hurdles that could impede product launches and market access. The company's significant negative profit margin indicates ongoing financial challenges, which may limit its ability to invest in growth initiatives. Additionally, intense competition from larger pharmaceutical companies poses a threat to DECN's market share, while its dependence on a niche market could restrict broader revenue growth opportunities.
How does Decision Diagnostics Corp. navigate regulatory approval processes?
Decision Diagnostics Corp. must adhere to stringent regulatory requirements for its medical devices and diagnostic products. This includes obtaining FDA approval for its glucose monitoring systems, which involves rigorous testing and documentation to demonstrate safety and efficacy. The company’s ability to navigate these processes effectively is crucial for timely product launches and maintaining compliance with healthcare regulations.
What are the key factors to evaluate for DECN?
Decision Diagnostics Corp. (DECN) holds an AI score of 48/100 (low). Not financial advice.
How frequently does DECN data refresh on this page?
DECN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DECN's recent stock price performance?
Decision Diagnostics Corp. (DECN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings in glucose monitoring. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DECN overvalued or undervalued right now?
Valuing Decision Diagnostics Corp. (DECN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DECN?
Before investing in Decision Diagnostics Corp. (DECN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial reporting and transparency due to OTC classification.